Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2002-07-12
2003-07-29
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S490000, C424S493000, C424S494000, C424S497000, C424S499000, C424S501000, C514S291000, C514S297000, C514S970000
Reexamination Certificate
active
06599535
ABSTRACT:
This invention relates to oral pharmaceutical compositions comprising a macrolide, e.g. a rapamycin or an ascomycin, in a solid dispersion.
Rapamycin is an immunosuppressive lactam macrolide produceable, for example by
Streptomyces hygroscopicus.
The structure of rapamycin is given in Kesseler, H., et al.; 1993
; Helv. Chim. Acta;
76: 117. Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability. Moreover, rapamycin is highly insoluble in aqueous media, e.g. water, making it difficult to formulate stable galenic compositions. Numerous derivatives of rapamycin are known. Certain 16-O-substituted rapamycins are disclosed in WO 94/02136, the contents of which are incorporated herein by reference. 40-O-substituted rapamycins are described in, e.g., in U.S. Pat. No. 5,258,389 and WO 94/09010 (O-aryl and O-alkyl rapamycins); WO 92/05179 (carboxylic acid esters), U.S. Pat. No. 5,118,677 (amide esters), U.S. Pat. No. 5,118,687 (carbamates), U.S. Pat. No. 5,100,883 (fluorinated esters), U.S. Pat. No. 5,151,413 (acetals), U.S. Pat. No. 5,120,842 (silyl ethers), WO 93/11130 (methylene rapamycin and derivatives), WO 94/02136 (methoxy derivatives), WO 94/02385 and WO 95/14023 (alkenyl derivatives) all of which are incorporated herein by reference. 32-O-dihydro or substituted rapamycin are described, e.g., in U.S. Pat. No. 5,256,790, incorporated herein by reference.
Further rapamycin derivatives are described in PC application number EP96/02441, for example 32-deoxorapamycin as described in Example 1, and 16-pent-2-ynyloxy-32(S)-dihydrorapamycin as described in Examples 2 and 3. The contents of PCT application number EP96/02441 are incorporated herein by reference.
Rapamycin and its structurally similar analogues and derivatives are termed collectively herein as “rapamycins”.
On oral administration to humans, solid rapamycins, e.g. rapamycin, may not be absorbed to any significant extent into the bloodstream. Simple mixtures are known for rapamycins, e.g. rapamycin, with conventional pharmaceutical excipients; however, disadvantages encountered with these compositions include unpredictable dissolution rates, irregular bioavailability profiles, and instability. To date there is no conveniently administrable oral solid formulation available for rapamycin or a derivative thereof.
Accordingly, in one aspect, this invention provides a pharmaceutical composition in the form of a solid dispersion comprising a rapamycin and a carrier medium.
The compositions of this invention provide a high bioavailability of drug substance, are convenient to administer, and are stable.
REFERENCES:
patent: 3852421 (1974-12-01), Koyanagi et al.
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 4248856 (1981-02-01), Guley et al.
patent: 4309404 (1982-01-01), DeNeale et al.
patent: 4309405 (1982-01-01), Guley et al.
patent: 4415547 (1983-11-01), Yu et al.
patent: 4421738 (1983-12-01), Yamagiwa et al.
patent: 4650666 (1987-03-01), Izutsu et al.
patent: 4753801 (1988-06-01), Oren et al.
patent: 4916138 (1990-04-01), Ueda et al.
patent: 5026560 (1991-06-01), Makino et al.
patent: 5078999 (1992-01-01), Warner et al.
patent: 5100883 (1992-03-01), Schiehser
patent: 5100899 (1992-03-01), Calne
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5260301 (1993-11-01), Nakanishi et al.
patent: 5286730 (1994-02-01), Caufield et al.
patent: 5352783 (1994-10-01), Shafiee et al.
patent: 5384130 (1995-01-01), Kamada
patent: 5387589 (1995-02-01), Kulkarni
patent: 5456923 (1995-10-01), Nakamichi et al.
patent: 5457111 (1995-10-01), Luly et al.
patent: 5457194 (1995-10-01), Luly et al.
patent: 5472954 (1995-12-01), Loftsson
patent: 5514686 (1996-05-01), Mochizuki et al.
patent: 5516770 (1996-05-01), Waranis et al.
patent: 5530006 (1996-06-01), Waranis et al.
patent: 5536729 (1996-07-01), Waranis et al.
patent: 5547948 (1996-08-01), Barcomb
patent: 5559121 (1996-09-01), Harrison et al.
patent: 5616588 (1997-04-01), Waranis et al.
patent: 5665772 (1997-09-01), Cottens et al.
patent: 5686110 (1997-11-01), Greenwald et al.
patent: 5691334 (1997-11-01), Doria et al.
patent: 5725883 (1998-03-01), Staniforth et al.
patent: 5759576 (1998-06-01), Barcomb
patent: 5759577 (1998-06-01), Barcomb
patent: 5766623 (1998-06-01), Ayres et al.
patent: 5776495 (1998-07-01), Duclos et al.
patent: 5780062 (1998-07-01), Frank et al.
patent: 5817333 (1998-10-01), Kagayama et al.
patent: 5932243 (1999-08-01), Fricker et al.
patent: 5985325 (1999-11-01), Nagi
patent: 5989591 (1999-11-01), Nagi
patent: 6004973 (1999-12-01), Guitard et al.
patent: 6262127 (2001-07-01), Acemoglu et al.
patent: 2164100 (1995-01-01), None
patent: 2170748 (1995-03-01), None
patent: 44 18 115 (1994-12-01), None
patent: 43 22 826 (1995-01-01), None
patent: 43 29 503 (1995-03-01), None
patent: 041 795 (1981-12-01), None
patent: 240 743 (1987-10-01), None
patent: 9240773 (1987-10-01), None
patent: 393 575 (1990-10-01), None
patent: 427 680 (1991-05-01), None
patent: 507 555 (1992-10-01), None
patent: 525 960 (1993-02-01), None
patent: 533 433 (1993-03-01), None
patent: 586 310 (1993-11-01), None
patent: 648 494 (1995-04-01), None
patent: 649 659 (1995-04-01), None
patent: 350 730 (1995-05-01), None
patent: 722 720 (1996-07-01), None
patent: 2 722 984 (1996-02-01), None
patent: 2278780 (1994-12-01), None
patent: 2279006 (1994-12-01), None
patent: 03-240726 (1991-10-01), None
patent: WO 91/16882 (1991-11-01), None
patent: WO 92/00739 (1992-01-01), None
patent: WO 92/02229 (1992-02-01), None
patent: WO 93/19763 (1993-10-01), None
patent: WO 96/14833 (1996-05-01), None
patent: WO 96/24332 (1996-08-01), None
patent: WO 96/25150 (1996-08-01), None
patent: WO 96/41807 (1996-12-01), None
patent: WO 97/02017 (1997-01-01), None
patent: WO 97/03654 (1997-02-01), None
“Remington's Pharmaceutical Sciences”, Fifteenth Edition, pp. 1422-1423, Mack Publishing Co. (1975).*
Derwent Abstract 94-033829/04 (TW 207954-A, Jun. 21, 1993).
Remingtons Pharmaceutical Sciences, 14thEdition, p. 1588 (1975).
Chiou et al., “Pharmaceutical Applications of Solid Dispersion Systems”, J. Pharm. Sci., vol. 60, No. 9, pp. 1281-1302 (1971).
Ford, “The Current Status of Solid Dispersions”, pharm. Acta. Helv., vol. 61, No. 3, pp. 68-88 (1986).
Approved Drug Products, 20th Edition, Prescription Drug Product List, pp. 3-311 (2000).
Derwent Abstract 96-335278 (EP722 720, Jul. 24, 1996).
Hahn et al., “Solid Surfactant Solutions of Active Ingredients in Sugar Esters”, Pharm. Res., vol. 6, No. 11, pp. 958-960 (1989).
Serajuddin, “Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems, and Recent Breakthrough”, J. Pharm. Sci., vol. 88, No. 10, pp. 1058-1066 (1999).
Guitard Patrice
Haeberlin Barbara
Link Rainer
Richter Friedrich
Krass Frederick
Novartis AG
Thallemer John D.
LandOfFree
Pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3105206